Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

BackgroundLiposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyclines. Randomized controlled trials have evaluated the efficacy and safety profile of liposomal formulations with conventional anthracyclines. Our aim is to evaluate the adverse effects and quantify the relative safety profile of the liposomal and conventional anthracyclines through meta-analysis of the published randomized trials.MethodsWe conducted a broad search strategy of major electronic databases. We performed a meta- analysis of adverse effects on randomized controlled trials comparing liposomal formulation and conventional anthracyclines on different tumors. The primary outcome was the adverse effects including congestive heart failure (CHF), hematological toxicity, palmar-plantar erythrodysthesias (PPE), alopecia, nausea and vomiting. The odds ratios of the adverse effects were calculated separately and the overall odds ratio of the pooled data was calculated.ResultsWe identified nine randomized controlled trials comparing liposomal formulations and conventional anthracyclines. The study included 2220 patients, of which1112 patients were treated with liposomal formulations and 1108 were treated with conventional anthracyclines. We found that the liposomal formulations have low incidence of CHF(OR 0.34, 95% CI, 0.24–0.47), alopecia (OR 0.0.25, 95% CI, 0.0.10-0.62), neutropenia (OR 0.62, 95% CI, 0.45- 0.85),(OR 0.89, 95% CI, 0.71-1.125), and thrombocytopenia (OR 0.87, 95% CI, 0.61-1.25). The incidence of PPE was similar in both arms (OR 1.08, 95% CI, 0.11- 10.30).ConclusionsLiposomal doxorubicin and pegylated liposomal doxorubicin demonstrated favorable toxicity profiles with better cardiac safety and less myelosuppression, alopecia, nausea and vomiting compared with the conventional anthracyclines. The better therapeutic index of liposomal anthracyclines without compromising the efficacy makes it a favorable choice over conventional anthracyclines in elderly patients, patients with risk factors for cardiac disease and patients with prior use of anthracyclines.

[1]  M. Štěrba,et al.  Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.

[2]  Shinichirou Takahashi.  Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications , 2011, Journal of hematology & oncology.

[3]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[4]  Jia-ling Wang,et al.  Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo , 2009, Acta Pharmacologica Sinica.

[5]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[6]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  He Huang,et al.  A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome , 2011, Journal of hematology & oncology.

[8]  R. Rifkin,et al.  Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.

[9]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[10]  A. C. Dubbelman,et al.  Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z. Pavelic,et al.  Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. , 1993, In vivo.

[13]  Tamar Safra.  Cardiac safety of liposomal anthracyclines. , 2003, The oncologist.

[14]  Yue-hua Ma,et al.  Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights , 2010, Journal of hematology & oncology.

[15]  S. Chan,et al.  Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Dixon,et al.  Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Liposomal anthracyclines in metastatic breast cancer: clinical update. , 2003, The oncologist.

[18]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Blay,et al.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.

[20]  Hong-Xia Wang,et al.  A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma , 2011, Journal of hematology & oncology.

[21]  Shinichirou Takahashi.  Current findings for recurring mutations in acute myeloid leukemia , 2011, Journal of hematology & oncology.

[22]  M. Dimopoulos,et al.  Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  N. Harbeck,et al.  Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer , 2006, Oncology.

[24]  M. Bally,et al.  Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.

[25]  J. O’Shaughnessy,et al.  Liposomal anthracyclines for breast cancer: overview. , 2003, The oncologist.

[26]  I. Fidler,et al.  Liposomes in the therapy of infectious diseases and cancer , 1989 .

[27]  Theresa M Allen,et al.  Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.

[28]  M. Bally,et al.  Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin , 2004, Cancer Chemotherapy and Pharmacology.

[29]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[30]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Z. Pavelic,et al.  Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. , 1993, In vivo.